Edwards Lifesciences Corporation $EW Shares Sold by State of New Jersey Common Pension Fund D

Key Points

• The State of New Jersey Common Pension Fund D reduced its holdings in Edwards Lifesciences Corporation by 11.2%, owning 200,319 shares valued at approximately $14.52 million after selling 25,143 shares in the 1st quarter.
• Edwards Lifesciences reported $1.53 billion in revenue for the quarter, exceeding estimates, with earnings of $0.67 per share, surpassing the consensus forecast of $0.62.
• Analysts have rated Edwards Lifesciences with an average target price of $85.90, with 13 buy and 3 strong buy ratings indicating a generally positive outlook on the stock.

State of New Jersey Common Pension Fund D lessened its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 11.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 200,319 shares of the medical research company's stock after selling 25,143 shares during the quarter. State of New Jersey Common Pension Fund D's holdings in Edwards Lifesciences were worth $14,519,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vega Investment Solutions purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $27,000. SouthState Corp purchased a new stake in Edwards Lifesciences in the 1st quarter valued at about $27,000. Global X Japan Co. Ltd. grew its holdings in Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after buying an additional 216 shares during the period. Tradewinds Capital Management LLC grew its holdings in Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after buying an additional 205 shares during the period. Finally, Rossby Financial LCC purchased a new stake in Edwards Lifesciences in the 1st quarter valued at about $29,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 2,570 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the transaction, the vice president directly owned 50,356 shares of the company's stock, valued at $3,897,554.40. This represents a 4.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,584 shares of company stock valued at $1,897,762 in the last three months. Corporate insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on EW. BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target for the company in a report on Tuesday, July 29th. Daiwa America upgraded Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 29th. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Truist Financial boosted their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a report on Friday, July 25th. Finally, Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of "Moderate Buy" and an average price target of $85.90.

Edwards Lifesciences Stock Down 0.3%

Edwards Lifesciences stock traded down $0.2320 during midday trading on Thursday, hitting $81.1580. 4,021,754 shares of the company were exchanged, compared to its average volume of 4,500,233. The company's fifty day moving average price is $77.35 and its 200-day moving average price is $74.54. The company has a market cap of $47.65 billion, a PE ratio of 11.68, a price-to-earnings-growth ratio of 3.81 and a beta of 1.08. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.